Alto Neuroscience, Inc. ANRO
ANRO Rating
ANRO Rating Factors
ANRO Company Overview
Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biotechnology company focused on developing precision psychiatry treatments for mental health conditions such as major depressive disorder (MDD), bipolar depression, schizophrenia, and post-traumatic stress disorder (PTSD). The company operates within the biotechnology and central nervous system (CNS) therapeutics industries, emphasizing biomarker-driven drug development intended to match patients with therapies based on measurable biological and neurophysiological characteristics. Its primary revenue and enterprise value drivers are tied to the advancement of its clinical-stage pipeline, intellectual property portfolio, and strategic development capabilities rather than commercialized products.
Alto Neuroscience was founded in 2019 by psychiatrist and neuroscientist Dr. Amit Etkin, who previously led research efforts at Stanford University focused on neurobiology and psychiatric disorders. The company evolved around the concept that psychiatric drug development could achieve improved clinical outcomes through patient stratification using biomarkers such as electroencephalography (EEG), neurocognitive assessments, digital phenotyping, and other objective measures. Alto completed its initial public offering in 2024 and has positioned itself as a precision medicine-focused CNS developer seeking differentiation from traditional psychiatry drug companies that rely on broader population-based clinical approaches.
ANRO Income Statement
ANRO Balance Sheet
ANRO Price History
ANRO Valuation
ANRO Dividends and Shares
ANRO Corporate Info
Suite 450
Mountain View, CA 94041